Anavex Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Year Ending	TTM	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	2018 - 2005
Net Income	-40.59	-47.51	-47.98	-37.91	-26.28	-26.29	Upgrade
Share-Based Compensation	11.99	16.37	18.38	8.23	4.88	6.43	Upgrade
Other Operating Activities	-3.87	3.35	5.36	-0.71	0.12	1.34	Upgrade
Operating Cash Flow	-32.48	-27.79	-24.24	-30.38	-21.29	-18.53	Upgrade
Share Issuance / Repurchase	18.4	29.65	22	158.79	28.75	17.83	Upgrade
Other Financing Activities	-	-	-0.71	-5.55	-0.4	-0.05	Upgrade
Financing Cash Flow	18.4	29.65	21.29	153.24	28.35	17.78	Upgrade
Net Cash Flow	-14.08	1.87	-2.95	122.86	7.06	-0.75	Upgrade
Free Cash Flow	-32.48	-27.79	-24.24	-30.38	-21.29	-18.53	Upgrade
Free Cash Flow Per Share	-0.39	-0.35	-0.32	-0.43	-0.37	-0.38	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).